CLDN7 and ovarian carcinoma: It is worth emphasizing that high expression of claudin-7 in ovarian carcinoma cells causes reduced response to first-line platinum-based combination chemotherapy, and silencing of its expression leads to increased sensitivity to cisplatin [124], confirming its involvement in the response to chemotherapy.